Jinlong Zhao, Lingfeng Zeng, Ming Wu, Hetao Huang, Guihong Liang, Weiyi Yang, Jianke Pan, Jun Liu
Journal: Complementary therapies in clinical practice 2021;44():101419
PMID: 34049211
BACKGROUND AND PURPOSE
Chinese patent medicines (CPMs) have gained increasing attention for the treatment of primary osteoporosis (POP), but there is a lack of high-quality evidence regarding their efficacy. We conducted a network meta-analysis that considered both direct and indirect comparisons to assess and rank the efficacy and safety of CPMs for POP.
METHODS
Seven electronic databases were searched from their inception to May 2020. A random effects model was applied within a frequentist framework.
RESULTS
Thirty-eight studies with 16 kinds of medicines (13 CPMs, 3 Western medicines) and 3,941 patients were included in this study. This study showed that Jintiange capsule was the most efficacious for increasing the L2-L4 average bone mineral density (BMD) and that Zuogui Wan was the most efficacious for increasing the femoral neck BMD. Compared with calcium, Gusongjiangu Wan (RR = 10.04, 95% CI 1.36-74.32, p = 0.008), Gushukang granules (RR = 12.63, 95% CI 2.02-78.99, p = 0.015) and Xianling Gubao capsule (RR = 6.06, 95% CI 1.38-26.65, p = 0.0003) had fewer adverse reactions.
CONCLUSION
In the treatment of POP, Jintiange capsule and Zuogui Wan are effective CPMs for improving the BMD of the lumbar spine and femoral neck, respectively.
Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved.
Full Text Sources:
Medical:
Other Literature Sources:
Full Text Sources:
© Copyright 2026, Nutrition Evidence
We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.